• Search

Discovery Stems From Here

Find your tools for building human cell-based models & screening assays

Welcome to Axol Bioscience

YOUR HUMAN CELL CULTURE SPECIALISTS

Our mission is to create the best human cell biology research tools, to advance medical research and drug discovery

Latest News

  • Layers of complexity: differentiating iPSCs into derivatives of the embryonic germ layers

    Through the previous blogs in this series, we have understood the challenges which somatic cells face when changing their career path to become induced pluripotent stem cells (iPSCs), the ways in which we can induce this change, and how we might assess whether this is the right career for the cells through pluripotency and differentiation assays.

  • Assessing the pluripotency and the differentiation potential of iPSCs

    In our previous blog we likened somatic cell reprogramming to a career change. Once a somatic cell has been converted to an induced pluripotent stem cell (iPSC), the next stage in the process can be thought of as an appraisal or performance review. This is essential to confirming that the reprogrammed cell is behaving as expected.

  • iPSC-derived male and female cardiomyocytes for cardiovascular research

    Cardiovascular diseases (CVD) include coronary heart disease, stroke, myocardial infarction and heart failure. They are the leading cause of mortality globally, with CVD accounting for 31% of deaths worldwide in 2015. Within the UK alone 27.4% of male deaths and 25.2% of female deaths in 2015 were due to CVD.

  • Interactive Stem Cell Forum

    Axol Bioscience is meeting Metrion Biosciences for a whole day stem cell event, on May 23, 2018. Don't miss the opportunity to see some excellent scientific presentations.

  • Human iPSC-derived cardiomyocytes: studying cardiomyocytes in vitro

    Traditionally, there have been difficulties in obtaining and culturing human cardiac cells of a high quality due to a scarcity of healthy donor material, culture issues associated with the non-dividing state of terminally differentiated cardiomyocytes. The development of human embryonic stem cell technology allowed major advancements to be made as protocols were developed to differentiate cardiomyocytes from a replenishable pluripotent source. A huge issue with the use of human embryonic stem cell-derived cells was the controversial ethical issues and strict regulations regarding their use. This meant that Yamanaka's breakthrough when his group produced the Nobel Prize winning technology in the form of induced pluripotent stem cells had a gargantuan impact on the study of human cardiac cells.